Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant carboplatin, paclitaxel, and radiotherapy in locally advanced gastric cancer
NL-OMON31088Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in gastric cancer (GC), sponsored by Netherlands Cancer Institute. Primary endpoints: Efficacy and Safety. Planned start Dec 2007; status: not yet recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON31088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31088.